Related Experiment Video
Updated: Jun 1, 2026

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers
Published on: September 19, 2022
Tripropeptin C blocks the lipid cycle of cell wall biosynthesis by complex formation with undecaprenyl pyrophosphate
Hideki Hashizume1, Ryuichi Sawa, Shigeko Harada
1Drug Development Unit, Bioactive Molecule Research Group, Laboratory of Disease Biology, Institute of Microbial Chemistry, Tokyo, Japan. hashizumeh@bikaken.or.jp
Abstract:
Tripropeptin C (TPPC) is a naturally occurring cyclic lipodepsipeptide antibiotic produced by a Lysobacter sp. TPPC exhibits potent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and penicillin-resistant Streptococcus pneumoniae. This antibiotic also inhibits the incorporation of N-acetylglucosamine into the peptidoglycan of S. aureus at a 50% inhibitory concentration (IC(50)) of 0.7 μM, which is proportional to its MIC (0.87 μM; equivalent to 1.0 μg/ml). Treatment of exponential-phase S. aureus cells with TPPC resulted in accumulation of UDP-MurNAc-pentapeptide in the cytoplasm. The antimicrobial activity of TPPC was weakened by the addition of prenyl pyrophosphates but not by prenyl phosphates, UDP-linked sugars, or the pentapeptide of peptidoglycan. The direct interaction between TPPC and undecaprenyl pyrophosphate (C(55)-PP) was observed by mass spectrometry and thin-layer chromatography analysis, indicating that TPPC can potentially inhibit C(55)-PP phosphatase activity, which plays a crucial role in the lipid cycle of peptidoglycan synthesis. As expected, TPPC inhibits this enzymatic reaction at an IC(50) of 0.03 to 0.1 μM in vitro, as does bacitracin. From the analysis of accumulation of lipid carrier-related compounds, TPPC was found to cause the accumulation of C(55)-PP in situ, leading to the accumulation of a glycine-containing lipid intermediate. This suggested that the TPPC/C(55)-PP complex also inhibits the transglycosylation step or flippase activity, adding to the inhibition of C(55)-PP dephosphorylation. This mode of action is different from that of currently available drugs such as vancomycin, daptomycin, and bacitracin.
Insights
Tripropeptin C (TPPC) is a novel cyclic lipodepsipeptide antibiotic effective against resistant bacteria like MRSA. It disrupts bacterial cell wall synthesis by inhibiting undecaprenyl pyrophosphate dephosphorylation and potentially other key steps.
Area of Science:
- Microbiology
- Biochemistry
- Drug Discovery
Background:
- Antibiotic resistance is a growing global health threat, necessitating the discovery of new antimicrobial agents.
- Naturally occurring compounds offer a promising source for novel antibiotics with unique mechanisms of action.
- Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and penicillin-resistant Streptococcus pneumoniae are critical pathogens with limited treatment options.
Purpose of the Study:
- To investigate the antibacterial activity and mechanism of action of Tripropeptin C (TPPC), a cyclic lipodepsipeptide antibiotic.
- To elucidate the specific molecular targets and pathways inhibited by TPPC in bacterial pathogens.
- To compare the mode of action of TPPC with existing antibiotics.
Main Methods:
- Antibacterial susceptibility testing against resistant bacterial strains (MRSA, VRE, S. pneumoniae).
- Enzyme inhibition assays to determine the IC(50) for peptidoglycan synthesis and C(55)-PP phosphatase activity.
- Cellular accumulation studies using mass spectrometry and thin-layer chromatography to analyze metabolic intermediates.
- In vitro biochemical assays to assess interactions with undecaprenyl pyrophosphate (C(55)-PP).
Main Results:
- TPPC demonstrated potent activity against MRSA, VRE, and penicillin-resistant S. pneumoniae.
- TPPC inhibited N-acetylglucosamine incorporation into peptidoglycan and caused cytoplasmic accumulation of UDP-MurNAc-pentapeptide.
- TPPC directly interacted with C(55)-PP, inhibiting C(55)-PP phosphatase activity with an IC(50) of 0.03–0.1 μM.
- TPPC treatment led to C(55)-PP accumulation and inhibition of transglycosylation or flippase activity.
Conclusions:
- TPPC represents a novel class of antibiotics targeting bacterial cell wall synthesis through a unique multi-step inhibition mechanism.
- Its distinct mode of action, involving C(55)-PP phosphatase inhibition and potential downstream effects, differentiates it from current antibiotics.
- TPPC holds potential as a therapeutic agent against multidrug-resistant bacterial infections.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Peptidoglycan Synthesis
Biosynthesis of Lipids
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Inhibitors of Bacterial Protein Synthesis

